Biotech News News 12 November 2025

Q32 Bio (QTTB) Stock Explodes After $592 Million Akebia Deal – Latest News, Analyst Targets and 2027 Outlook

On December 1, 2025, Q32 Bio Inc. (NASDAQ: QTTB) suddenly became one of the most-watched small-cap biotech stocks on Wall Street. Shares of Q32 Bio surged intraday by roughly 90%–170% at various points in Monday’s session, with trading volume soaring

1 December 2025

Biotech News·Financial Outlook·Investment Analysis·Mergers & Acquisitions·Stock Market

AbbVie (ABBV) Stock Today: Price, Analyst Views, Medicare News and New Biotech Award – November 25, 2025

AbbVie Inc. (NYSE: ABBV) ended Tuesday, November 25, 2025, on a firmer footing, closing at $231.80, up about 1.0% on the day and recovering some of Monday’s pullback. The move came amid a flurry of fresh headlines: U.S. Medicare confirmed

25 November 2025

Analyst Opinions·Biotech News·Investment Insights·Stock Market

ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment

Key Takeaways ALT stock price today: how Altimmune is trading on November 25, 2025 Altimmune Inc. (NASDAQ: ALT) continues its November rebound. As of early trading on Tuesday, November 25, ALT is changing hands around $5.1 per share, roughly flat

25 November 2025

Biotech News·FDA Updates·Investing·Pharmaceutical Industry·Stock Market

TNXP Stock Today (Nov. 25, 2025): Tonix Slips as Wall Street Weighs MDD IND Win, Tonmya Launch, and Dilution Risk

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) had a busy news day on Monday — and the stock still finished sharply lower. Shares of the small-cap biotech closed around $14.29 on November 25, 2025, down roughly 11% on the session, putting

25 November 2025

Biotech News·Company Updates·Financial Analysis·Investing·Stock Market

CLSD Stock Crashes Over 60% Today as Clearside Biomedical Files for Chapter 11 Bankruptcy

Monday, November 24, 2025 Clearside Biomedical’s CLSD stock is in freefall today after the eye‑disease biotech announced a voluntary Chapter 11 bankruptcy filing and plans to pursue a court‑supervised sale of its business and assets. By late afternoon on Monday,

24 November 2025

Bankruptcy·Biotech News·Financial News·Investment Analysis·Stock Market

OSR Holdings (OSRH) Jumps Over 15% Today on Vaximm Deal Momentum: Stock Price, Nasdaq Risk and What Comes Next

OSR Holdings, Inc. (NASDAQ: OSRH) is back on traders’ screens today, November 24, 2025, with the micro-cap healthcare stock extending last week’s rally sparked by its cancer-immunotherapy subsidiary Vaximm AG. As of early afternoon U.S. trading on Monday, OSRH is

24 November 2025

Biotech News·Financial Analysis·Investing·Nasdaq·Stock Market

Novavax Stock (NVAX) on November 24, 2025: Price, Sanofi Deal, Shah Capital Pressure and What It All Means for Investors

All figures current as of the U.S. market close on Friday, November 21, 2025. NVAX will next trade when markets reopen on Monday, November 24, 2025. Quick snapshot for NVAX heading into November 24, 2025 Novavax stock price today: where

24 November 2025

Biotech News·Financial Analysis·Investing·Stock Market

Moderna (MRNA) Stock Today, November 23, 2025: Short-Seller Pressure, $1.5 Billion Loan and mRNA Pipeline Reset

Moderna Inc. (NASDAQ: MRNA) enters Sunday, November 23, 2025, as one of the most controversial and heavily shorted stocks in the S&P 500. The biotech is trading near its 52‑week low after the COVID‑vaccine boom faded, yet it’s rolling out

23 November 2025

Biotech News·Financial Updates·Investment Analysis·Pharma Industry·Stock Market

Nuvation Bio (NUVB) Rockets to 3‑Year High as Wall Street Lifts Price Targets on IBTROZI Momentum – November 20, 2025

Nuvation Bio Inc. has become one of the hottest tickers in biotech this week. On November 20, 2025, NUVB is trading near a three‑year high after a powerful earnings beat, accelerating uptake of its lung‑cancer drug IBTROZI™ (taletrectinib), and a

20 November 2025

Biotech News·Financial Analysis·Investment Strategies·Stock Market·Wall Street

Anavex Life Sciences (AVXL) Stock Plunges After EMA Issues Negative Trend Vote on Alzheimer’s Drug

Anavex Life Sciences (NASDAQ: AVXL) tumbled on November 14, 2025 after Europe’s drug regulator delivered a negative trend vote on its Alzheimer’s candidate blarcamesine. The company plans a CHMP re-examination and a fresh meeting with the FDA. Here’s what happened

14 November 2025

Biotech News·Investment Analysis·Pharmaceuticals·Stock Market

Mersana Therapeutics (MRSN) Soars on Up to $285 Million Day One Biopharmaceuticals Buyout: All the Key News on November 13, 2025

Mersana Therapeutics (NASDAQ: MRSN) is back in the headlines in a big way today after announcing a definitive agreement to be acquired by Day One Biopharmaceuticals in a deal worth up to approximately $285 million. The news has sent MRSN

13 November 2025

Biotech News·Mergers & Acquisitions·Pharmaceutical Industry

Salarius Pharmaceuticals (SLRX) Stock Jumps as $7M Offering Prices; Closing Expected November 12, 2025 Amid Decoy Therapeutics Merger

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) is back in the headlines today after pricing a $7 million underwritten public offering tied to its pending business combination with Decoy Therapeutics. The company said the deal is expected to close “on or about

12 November 2025

Biotech News·Investment·Mergers & Acquisitions·Pharmaceuticals·Stock Market

Biotech News News 12 November 2025 - 1 December 2025